echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Hengrui Medicine's Class 1 new drug SHR8008 Capsule's second indication was approved for clinical use

    Hengrui Medicine's Class 1 new drug SHR8008 Capsule's second indication was approved for clinical use

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Recently, Hengrui Medicine announced that its class 1 new drug SHR8008 capsules has been approved by the National Medical Products Administration to carry out a phase III clinical trial for the treatment of acute vulvovaginal candidiasis.

    This is the second indication after SHR8008 capsules were approved to carry out clinical research for recurrent vulvovaginal candidiasis (RVVC) in 2020.

    Vulvovaginal candidiasis (VVC) is an inflammatory disease caused by a fungal infection dominated by Candida albicans.

    Approximately 75% of women will suffer from VVC once in their lifetime, and 40% to 50% will relapse again.
    The clinical manifestations may include genital itching, burning pain, increased vaginal discharge, painful urination, etc.
    , which seriously affects the quality of life.

    At present, the clinical application of existing treatment methods is limited, and there is an urgent need to develop a new generation of safer and more effective oral antifungal drugs.

    SHR8008 is a new type of oral azole antifungal drug originally developed by Mycovia Company.
    It is significantly better than the commonly used azole antifungal drugs in inhibiting the fungal CYP51 enzyme.

    In 2019, Hengrui Pharmaceuticals spent 110 million US dollars to introduce the product and obtained the exclusive rights to clinical development, registration, production and marketing of the compound in China.

    Clinical trials have shown that SHR8008 has shown good safety and tolerability in multiple study populations.

    From the results of Phase II clinical studies, SHR8008 can effectively treat acute VVC attacks.

    Based on the above results, Hengrui Medicine plans to carry out a phase III clinical study of SHR8008 in the treatment of acute vulvovaginal candida disease in China, to further evaluate the effectiveness and safety of SHR8008 capsules in the treatment of acute VVC, and to provide more treatment for patients with acute VVC Clinical choice.

    End reference materials: [1] Hengrui Medicine WeChat public account selected onlookers to exercise in the past is really important! Cell sub-news reveal: Skeletal muscle can delay brain and retina aging in a specific way.
    Hot article April 2 | World Autism Day, the children who guard the stars together | An overview of the performance of 26 unprofitable biomedical companies in Hong Kong stocks in 2020 Is it necessary to exercise more than one? Cell Sub-Journal: Excessive exercise can cause damage to the mitochondrial function of healthy people and impair glucose tolerance.
    It’s no wonder that the more you eat, the fatter you get! Science reveals: The intestine regulates nutritional metabolism according to eating conditions.
    This cell is the key "modulator".
    Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical Technology | Basic Research on Drug Side Effects/Translational Medicine Leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbiological Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-nano| 3D printing| Genetic testing| Single-cell sequencing| Gene editing| Assisted reproduction| Artificial intelligence| Precision medicine policy anticancer drugs| 4+7 volume procurement| Consumables| Filing system| Registrant system| Healthy China| New edition Essential medicine catalog| AI medical equipment| Telemedicine| Equity non-equity market/capital IPO| Financing| Cooperation| Funds| Hong Kong Stock Exchange| Science and Technology Innovation Board| Growth Enterprise Market| R&D Investment| Acquisitions| Market & Consumption
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.